Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval

With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.